A bit of a mixed report really. Some good - revenue up, gross profit up. API revenue is looking very good.
I particularly DIDN'T like the 'we would had xx EBITDA if not for this, this and this' on page 11. Normalised EBITDA they call it, but aren't these issues a part of doing business? French customer order deferral, UK customer order deferral, CMO early termination. If not for the really, really fast bowling, I would've opened the batting for Australia!
- Forums
- ASX - By Stock
- Ann: Palla Pharma Investor Presentation - FY19 Results & Outlook
A bit of a mixed report really. Some good - revenue up, gross...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online